The man who is confused about his identity

doi:10.1017/9781108623872.002

Case 2: - The man who is confused about his identity

Published online by Cambridge University Press: 03 April 2024

Shiyu Chen

Edited by

Nevena V. Radonjić ,

Thomas L. Schwartz and

Stephen M. Stahl

Show author details

Nevena V. Radonjić: Affiliation:
State University of New York Upstate Medical University
Thomas L. Schwartz: Affiliation:
State University of New York Upstate Medical University
Stephen M. Stahl: Affiliation:
University of California, San Diego

Book contents

Get access

Summary

Does ketamine or esketamine worsen dissociation in patients with post-traumatic stress disorder (PTSD)?

Keywords

post-traumatic stress disorder generalized anxiety social anxiety depression treatment resistance combination psychotherapy sertraline (Zoloft)alprazolam (Xanax)zolpidem (Ambien)buspirone (Buspar)esketamine (Spravato)bupropion (Wellbutrin)

Type: Chapter
Information: Case Studies: Stahl's Essential Psychopharmacology , pp. 21 - 38

DOI: https://doi.org/10.1017/9781108623872.002 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Albott, CS, Lim, KO, Forbes, MK, et al. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry 2018; 79:17m11634CrossRef Google Scholar PubMed

Aleksandrova, LR, Phillips, AG, Wang, YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci 2017; 42:222–9CrossRef Google Scholar PubMed

Browne, CA, Lucki, I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013; 4:161CrossRef Google Scholar PubMed

Canuso, CM, Singh, JB, Fedgchin, M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018; 175:620–30CrossRef Google Scholar PubMed

Collins, A, Rutter, S, Feder, A. Development of ketamine administration as a treatment for chronic PTSD. Psychiatric Annals 2020; 50:68–76CrossRef Google Scholar

Feder, A, Parides, MK, Murrough, JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71:681–8CrossRef Google Scholar PubMed

Henter, ID, de Sousa, RT, Zarate, CA, Jr. Glutamatergic modulators in depression. Harv Rev Psychiatry 2018; 26:307–19CrossRef Google Scholar PubMed

Hidalgo, R, Hertzberg, MA, Mellman, T, et al. Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol 1999; 14:61–8CrossRef Google Scholar PubMed

Kew, JN, Kemp, JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005; 179:4–29CrossRef Google Scholar PubMed

Kim, J, Farchione, T, Potter, A, et al. Esketamine for treatment-resistant depression – first FDA-approved antidepressant in a new class. N Engl J Med 2019; 381:1–4CrossRef Google Scholar PubMed

Liriano, F, Hatten, C, Schwartz, TL. Ketamine as treatment for post-traumatic stress disorder: a review. Drugs Context 2019; 8:212–305CrossRef Google Scholar PubMed

Murrough, JW, Perez, AM, Pillemer, S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74:250–6CrossRef Google Scholar PubMed

Rasmussen, KG. Ketamine for posttraumatic stress disorder. JAMA Psychiatry 2015; 72:94–5CrossRef Google Scholar PubMed

Sartori, SB, Singewald, N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019; 204:107402CrossRef Google Scholar PubMed

Sattar, Y, Wilson, J, Khan, AM, et al. A review of the mechanism of antagonism of N-methyl-D-aspartate receptor by ketamine in treatment-resistant depression. Cureus 2018; 10:e2652Google Scholar PubMed

Stahl, SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5. Cambridge: Cambridge University Press, 2021CrossRef Google Scholar

VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Washington, DC: Veterans’ Association, 2017Google Scholar